Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about JOUNCE THERAPEUTICS, INC.
10/07JOUNCE THERAPEUTICS : Initiates Enrollment of Phase 1 Trial Cohorts of JTX-8064
MT
10/07JOUNCE THERAPEUTICS : Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monother..
AQ
10/07Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monothe..
CI
09/15JOUNCE THERAPEUTICS : Departures of Directors or Certain Officers; Election of Directors; ..
PU
09/15JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/15Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
GL
09/15Jounce Therapeutics, Inc. Announces Board Changes
CI
09/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/14JOUNCE THERAPEUTICS : Raymond James Upgrades Jounce Therapeutics to Outperform From Market..
MT
09/02Jounce Therapeutics to Present at Upcoming Investor Conferences in September
GL
08/05JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/05Jounce Therapeutics Reports Second Quarter 2021 Financial Results
GL
08/05JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
08/05Jounce Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
CI
07/29Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Confer..
GL
07/07JOUNCE THERAPEUTICS : to Participate in William Blair's Biotech Focus Conference
AQ
06/25JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) dropped from Russell 2000 Value-Defensive Index
CI
06/25JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) dropped from Russell 2000 Defensive Index
CI
06/23JOUNCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/23Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, a..
GL
06/16Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
GL
06/15UPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA Clears Canc..
MT
06/15Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
DJ
06/15JOUNCE THERAPEUTICS : Set for $25 Million Milestone Payment from Gilead After Investigatio..
MT
06/15Wall Street Sees Muted Open Amid Data Deluge
MT
06/15GILEAD SCIENCES : Jounce Therapeutics Achieves First Milestone in Exclusive License Agreem..
AQ
06/15Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead..
CI
06/15Jounce Therapeutics Gets FDA Clearance for Cancer Treatment IND
DJ
06/14Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health I..
GL
06/04Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinica..
GL
05/28JOUNCE THERAPEUTICS : JNCE) Insider Makes Significant Share Sale
MT
05/27INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Jounce Therapeutics
MT
05/08Certain Common Stock of Jounce Therapeutics, Inc. are subject to a Lock-Up Agreement En..
CI
05/08Certain Stock Options of Jounce Therapeutics, Inc. are subject to a Lock-Up Agreement E..
CI
05/08Certain Restricted Stock Units of Jounce Therapeutics, Inc. are subject to a Lock-Up Ag..
CI
05/04JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/04JOUNCE THERAPEUTICS : Reports Narrower Q1 Loss
MT
05/04JOUNCE THERAPEUTICS : Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LI..
PU
05/04JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
05/04Jounce Therapeutics Reports First Quarter 2021 Financial Results
GL
05/04Jounce Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/28Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the ..
GL
04/28Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 Innate and the ..
CI
04/27Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conferenc..
GL
04/12Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
GL
04/12Jounce Therapeutics, Inc. Appoints Dmitri Wiederschain as Chief Scientific Officer
CI
04/10Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 ..
GL
04/10Jounce Therapeutics, Inc. Presents Preclinical Data from JTX-8064/LILRB2 Program at the..
CI
03/15JOUNCE THERAPEUTICS : Piper Sandler Starts Jounce Therapeutics at Overweight With $20 Pric..
MT
03/12JOUNCE THERAPEUTICS : Closes Common Stock Offering, Raises $64.7 Million in Gross Proceeds
MT
03/12Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allo..
GL
03/11SECTOR UPDATE : Health Care Stocks Carried Higher By Biotech Companies
MT
03/11JOUNCE THERAPEUTICS : Rises on Plan to Present Preclinical JTX-8064 Data at Cancer Meeting
MT
03/11JOUNCE THERAPEUTICS : to Present Preclinical Data from JTX-8064 Program at the 2021 Americ..
AQ
03/10JOUNCE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
03/10Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 Ameri..
GL
03/10JOUNCE THERAPEUTICS : Prices Public Offering at $11.25/Share, Expects to Raise $56.3 milli..
MT
03/09Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
GL
03/09JOUNCE THERAPEUTICS : Plans Share Offering; Stock Dives 7% After Hours
MT
03/09Jounce Therapeutics Announces Proposed Offering of Common Stock
GL
02/25JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
02/25JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
02/25Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
GL
02/25Jounce Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended Decembe..
CI
02/23Jounce Therapeutics to Present at Upcoming Investor Conferences in March
GL
02/18Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and..
GL
02/15JOUNCE THERAPEUTICS : Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
AQ
02/12JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
02/12Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
GL
02/12Jounce Therapeutics Appoints Luisa Salter-Cid, to Its Board of Directors
CI
01/14JOUNCE THERAPEUTICS : Announces Initiation of Phase 1 INNATE Study of JTX-8064 Monotherapy..
AQ
01/13JOUNCE THERAPEUTICS : Initiates Phase 1 Study of JTX-8064 to Treat Solid Tumors
MT
01/13Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/IL..
GL
01/13Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/IL..
CI
01/11JOUNCE THERAPEUTICS : to Present at Upcoming Investor Conferences in January
AQ
1  2  3  4Next
Upcoming event on JOUNCE THERAPEUTICS, INC.